Pelthos (PTHS) files LNHC unaudited financials and pro forma data post-merger closed July 1, 2025

Pelthos Therapeutics Inc.

Merger closed July 1, 2025; issued ~31,278 Series A Preferred shares to Ligand; PIPE raised ~$50.1M gross.
LNHC unaudited balance sheets as of June 30, 2025 and 2024; pro forma financial info provided for combined entity.
ZELSUVMI (berdazimer gel) FDA approved Jan 2024 for molluscum contagiosum; 13% royalty to Ligand on worldwide sales.
Nomis RoyaltyVest receives 1.5% royalty on ZELSUVMI net sales; additional royalty agreements with Ligand and Madison.
Company holds exclusive license from Ligand for ZELSUVMI ex-Japan; 19,265 sq ft facility in Durham, NC.

item 9.01item 2.01item 2.02

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.